Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications.
Lidia StaszewskyMarta BavieraMauro TettamantiPierluca ColacioppoFabio RobustoAntonio D'EttorreVito LeporeIda FortinoLucia BiscegliaEttore AttoliniElisabetta Anna GrapsGianluca CaldoMaria Carla RoncaglioniSilvio GarattiniRoberto LatiniPublished in: BMJ open diabetes research & care (2022)
In patients with DM and HF, SGLT-2i and GLP-1RA significantly reduced MACE compared with insulin, and particularly any cause of death and first hospitalization for HF. These groups of medications had high safety profiles compared with other-AHAs and particularly with insulin. The inadequate optimization of HF and DM cotreatment in the insulin cohort is noteworthy.